Displaying 201–210 of 742 results
Mar 8, 2021
George was well-known in his community for his integrity and dedication to helping everyone around him.
Mar 2, 2021
Course Title: Clinical Trials of Emerging Therapies for Retinal Degeneration Patients: Hope and Opportunities
Feb 22, 2021
Charity’s recent rapid decline in vision due to RP and her daughter’s diagnosis with RP has caused her to open up about her vision loss journey. After getting involved with the Foundation, Charity now feels like she has a voice to help others in the visually impaired community.
Feb 17, 2021
His latest Foundation grant is helping move the drug toward a clinical trial
Feb 11, 2021
Therapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
Feb 8, 2021
Diagnosed with retinitis pigmentosa at a very young age, growing up, Erin never let her progressive vision loss stop her from keeping up with her friends and siblings. Throughout the 1990s, Erin was featured in several Foundation Fighting Blindness campaigns to raise funds for retinal research. Today, 34-year-old Erin is resilient as ever, still hopeful research will one day find her a cure.
Feb 4, 2021
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
Feb 3, 2021
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on January 29, 2021.
Feb 2, 2021
Researchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
Jan 29, 2021
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board